SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Encouraging early zugo-cel data in autoimmune diseases is drawing attention: traders highlight responses in systemic sclerosis and inflammatory myopathy, alongside a favorable initial safety read across 21 patients. Bulls see promise in the off-the-shelf CD19 CAR-T approach, while others stress that the small cohorts and early follow-up leave efficacy and safety to be confirmed.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is rebounding with South Korean equities and memory-chip stocks after a sharp AI-related selloff and forced deleveraging. Traders are debating whether the bounce signals stabilization or is temporary, with KOSPI volatility keeping sentiment cautious.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with the most common theme being swings in the broader Nasdaq and tech market: traders debate whether selloffs will deepen or give way to a rebound. Company-specific posts also point to recent quarterly results and Nasdaqs planned extended-hours trading, but neither clearly dominates the conversation.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline: traders are watching for further REGAIN glioblastoma data, updates from the completed-enrollment IMPACT pancreatic trial, ReSTART results, and a possible FDA IDE for the Keytruda combination. The community is broadly bullish on the upcoming milestones and recent share-price strength, though some are waiting for confirmed updates rather than speculating about the next announcement.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,805,873.7130931 in circulation. The last known price of Litecoin is 52.00804602 USD and is down -0.75 over the last 24 hours. It is currently trading on 1567 active market(s) with $117,565,973.29 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoins pullback and weak performance after earlier rallies are driving discussion, with traders parsing technical support and some treating the decline as an accumulation opportunity. Others argue LTC repeatedly gives back gains and may remain under pressure, while bullish breakout and squeeze calls remain speculative.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs quarterly results and raised full-year revenue guidance are drawing attention, alongside progress in its cancer pipeline as COVID-related revenue wanes. Traders see the update as support for its oncology transition, while others remain cautious about clinical execution and compare its performance unfavorably with Moderna.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AIs quarterly results beat expectations and the company raised its full-year revenue outlook, prompting a bullish reaction and heavy focus on call-option activity. Traders are debating whether momentum will continue or fade, while some remain cautious about volatility, valuation, and how quickly hospitals will adopt its AI products.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom is drawing attention ahead of earnings, with traders debating whether its AI products can drive new growth as rivals bundle similar meeting tools and companies trim paid seats. Skeptics see a mature, low-growth business with limited upsell potential, while others are watching the $90 level for a technical rebound.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Unusual options and elevated dark-pool activity are drawing attention, with traders noting fresh positioning on both calls and puts and debating whether the put flow reflects hedging or a bearish view. The broader discussion is directionally mixed, with some traders expecting further weakness and others watching for a rebound.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Attention centers on povetacicepts upcoming FDA decision for IgA nephropathy, following positive Phase 3 RAINIER results; traders are bullish on its potential as a new growth pillar, though approval and commercial upside remain uncertain. Q3 results also drew mixed reactions, with revenue growth and raised guidance weighed against an adjusted EPS miss and concerns about valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers agreement with Eli Lilly to offer Zepbound and Foundayo through its platform is driving attention, adding Lillys branded obesity drugs alongside Novo Nordisks products. Traders see the deal as expanding Hims weight-loss opportunity ahead of Q3 results, while some question its impact on margins and whether the partnership will translate into lasting growth.

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

Key PointsHims & Hers Health is leveraging a high-growth, subscription-based digital platform to provide personalized treatments for weight loss and sexual health...

HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance?

Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines Lilly and Hims & Hers expand access to FDA-approved Lilly medicinesPR NewswireINDIANAPOLIS, Nov. 6, 2026 Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformINDIANAPOLIS...

Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $24.06, indicating a -9.75% shift from the previous trading day.

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market

New HHS Direction Creates Potential Opportunities For Peptide Manufacturers, Biotech Companies, And Healthcare Innovators    New York, NY –November 5, 2026 – The federal government’s October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action against qualifying state-licensed pharmacies, federal […]
The post Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market appeared first on Financial News Media.

Hims & Hers Benefits Adds Grns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grns, Medjet, Tonal, and Viome. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers...

Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of +11.11% and +9.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims or the Company) (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that...

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (Hims & Hers or the Company) (NYSE: HIMS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...

Hims & Hers Health 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

Kahn Swick & Foti, LLC (KSF) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (Hims or the Company) (NYSE...

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six Peptides

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The compounding players must follow basic rules on ingredient quality, manufacturing, safety reporting, labeling, and prescriptions written for individual patients.&nbsp;</li><li>Hims has already prepared for a potential approval of peptide compounding by securing a California peptide facility and testing ingredients.</li><li>Hims CEO Andrew Dudum termed the news “encouraging progress.”</li></ul> Shares of Hims &amp; Hers (HIMS) jumped 5% on Wednesday after the Department of Health and Human Services said it would temporarily allow compounding pharmacies to produce six popular peptides.HHS said it will not go after state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—as long as they follow basic rules on ingredient quality, manufacturing, safety reporting, labeling, and prescriptions written for individual patients.“...based on the Pharmacy Compounding Advisory Committee (PCAC) meeting and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding,” HHS said, referring to the advisory committee recommendation in July that some peptides be considered for compounding.The new policy is temporary while the FDA completes formal rulemaking on the official list of bulk substances that can be used in compounding. Compounders must report serious adverse events with the use of the drugs or any product quality issues such as contamination to the FDA, HHS added. &nbsp;Compounded drugs are not FDA-approved.<h2 class="st-heading-2">How HIMS Is Positioned To Monetize The Move</h2>Hims has already prepared for a potential approval of peptide compounding by securing a California peptide facility and testing ingredients, while signaling interest in offering items such as sermorelin, glutathione, and NAD+ depending on final regulatory outcomes. Peptides used for recovery, inflammation, sleep, and related wellness goals have drawn strong consumer interest online, even without formal FDA approval.“We have spent years building the infrastructure we need in our very own US-based peptide manufacturing facility, developing dosing protocols with clinical experts, and setting up frameworks to better understand these emerging treatments,” the company’s Chief Medical Officer Anant Vinjamoori said after the HHS directive in a post on X. HIMS CEO Andrew Dudum also termed it “encouraging progress.”HIMS, however, has also faced setbacks this year, including an FTC lawsuit filed in late July alleging deceptive privacy practices involving data sharing with advertising platforms and misleading billing or cancellation practices. The company transitioned from offering compounded GLP-1s to branded versions earlier this year, pressuring margins despite subscriber growth.<h2 class="st-heading-2">How Did HIMS Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$HIMS" data-symbol-id="HIMS" href="https://stocktwits.com/symbol/HIMS" target="_blank">HIMS stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume increased from 'low' to 'normal' levels.A few Stocktwits users expressed anticipation for the company’s upcoming earnings.<stembedurl>https://stocktwits.com/Ramiz888817/message/667572047</stembedurl>Another termed the temporary clearance on peptide compounding “a bonus,” terming the stock cheap at its current valuation.<stembedurl>https://stocktwits.com/StoneFoxCapital/message/667565866</stembedurl>HIMS stock has fallen 8% year-to-date.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/prme-beam-edit-ntla-crsp-stocks-gain-as-fda-signals-faster-route-for-patient-specific-gene-edits/cZU9Y9vR9GV">PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HHS said it will not go after state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. 

Hims & Hers Health Inc

iShares Core S&P Mid-Cap ETF

Vanguard Total Stock Market ETF

Favorable

Unfavorable

Delayed

Hims & Hers ($HIMS) is bracing for a pivotal FDA advisory meeting on July 23-24 that will decide whether seven peptides get added to the compounding list. How do you think the FDA rules? Vote and explain your reasoning in the comments.

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for $HIMS. How do you think it goes?

Stocktwits

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for 

Current Price	$26.00
Prev Close	$24.06
Open	$25.78
Dividend Yield	0.00%
50-Day Moving Average	$28.43
Beta	2.40
Avg. Volume	9.76M
PE Ratio	-41.73

52-Week High	$42.70
52-Week Low	$13.74
Market Capitalization	$6.07B
EPS (Annual)	$0.5123
Price to Book	18.72
Revenue Per Employee	$961,358.31

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIMS Fundamentals